Related Experiment Video

Updated: Aug 21, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

[Interferon-beta treatment in patients with childhood-onset and juvenile multiple sclerosis]

N A Totolian, A A Skoromets

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |October 20, 2004
    PubMed

    Insights

    Pediatric multiple sclerosis (MS) shows a poor prognosis with severe disability and frequent relapses in juvenile patients. Beta-interferon treatment may offer benefits, but careful consideration of factors is needed.

    Area of Science:

    • Neurology
    • Immunology
    • Pediatrics

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Understanding the natural history and treatment outcomes in pediatric-onset MS is crucial for early intervention.

    Observation:

    • A prospective study observed 10 pediatric MS cases (onset age 10-16 years).
    • Juvenile MS exhibited a poor prognosis with severe disability and high relapse rates within two years post-onset.
    • Long-term (2.0-3.5 years) beta-interferon treatment was analyzed in these patients.

    Findings:

    • Juvenile MS demonstrates a more aggressive disease course compared to adult-onset MS.
    • Beta-interferon treatment outcomes varied, influenced by specific patient factors.
    • Analysis integrated findings from published adult-onset MS clinical trials.

    Implications:

    • Findings suggest potential benefits of beta-interferon therapy in juvenile MS.
    • Identifying factors influencing treatment response is key for personalized therapy.
    • This research informs treatment indications and therapeutic strategies for pediatric MS.

    Related Concept Videos

    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...